Genmab Announces Lift of Zalutumumab Partial Clinical Hold
17-Jul-2009
- Denmark
"We have worked diligently to meet the FDA's request for additional zalutumumab safety information and are pleased that enrolment in the studies can be resumed so quickly," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We continue to believe zalutumumab could provide an important new treatment option for head and neck cancer patients with unmet medical needs."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.